CLINACIN 300 MG TABLETS FOR DOGS

Nazione: Irlanda

Lingua: inglese

Fonte: HPRA (Health Products Regulatory Authority)

Principio attivo:

CLINDAMYCIN (AS CLINDAMYCIN HYDROCHLORIDE)

Commercializzato da:

Chanelle Animal Health Ltd.

Codice ATC:

QJ01FF01

INN (Nome Internazionale):

CLINDAMYCIN (AS CLINDAMYCIN HYDROCHLORIDE)

Dosaggio:

300 mg/tablet

Forma farmaceutica:

Tablets

Tipo di ricetta:

POM

Gruppo terapeutico:

Canine

Area terapeutica:

Clindamycin

Indicazioni terapeutiche:

Antibacterial

Stato dell'autorizzazione:

Authorised

Data dell'autorizzazione:

2007-06-01

Scheda tecnica

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Clinacin 300 mg Tablets for Dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
Active Substance:
Clindamycin (as Clindamycin Hydrochloride)
300 mg
Excipients:
For a full list of excipients see section 6.1
3 PHARMACEUTICAL FORM
Tablet
An oblong white to off white tablet with a break line on one side.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of: -
Infected wounds, abscesses and oral cavity/dental infections caused by or associated with clindamycin-sensitive species
of:
_Staphylococcus_
_Streptococcus_
_Bacteroides_
_Fusobacterium necrophorum_
_Clostridium perfringens_
Osteomyelitis
_Staphylococcus aureus_
4.3 CONTRAINDICATIONS
Do not use in cases of known hypersensitivity to all lincosamindes.
Do not administer to rabbits, hamsters, guinea pigs, chinchillas, horses or ruminants because ingestion of clindamycin
by these species may result in severe gastro-intestinal disturbance.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None known.
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 08/11/2016_
_CRN 7024937_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
During prolonged therapy of one month or greater, periodic liver and kidney function tests and blood counts should be
performed. Patients with severe renal and/or hepatic disturbances accompanied by severe metabolic aberrations should
be dosed with caution and should be monitored by serum examination during clindamycin therapy.
Whenever possible, the veterinary medicinal product should only be used based on suseptibility testing.
SPECIAL PRECAUTIONS